The Center for Biosimilars® recaps the top stories for the week of December 9, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 9, 2019.
Number 5: Increased spending on new oncology and autoimmune drugs was partially offset by a continued increase in the use of generics, according to a recent report from CMS.
Number 4: During this week’s 61st meeting of the American Society of Hematology, researchers reported on eculizumab, a prospective biosimilar, and a long-acting successor.
Number 3: Sanofi announced that it will stop research and development on diabetes drugs, but it will keep a proposed biosimilar of insulin aspart in its pipeline as a registration-phase molecule.
Number 2: An agreement on the United States—Mexico–Canada Agreement has been reached, and it excludes controversial terms for biologics.
Number 1: The FDA has approved Amgen’s infliximab biosimilar, Avsola, the fourth biosimilar infliximab and the 26th US biosimilar.
Finally, last week, our e-newsletter asked how great an impact you think subcutaneously administered biosimilar infliximab will have on clinical practice.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.